Should we customize the treatment with interleukin-17A inhibitors for moderate-to-severe psoriasis in the real-world setting?

J Eur Acad Dermatol Venereol. 2023 Feb;37(2):e262-e263. doi: 10.1111/jdv.18678. Epub 2022 Oct 31.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Monoclonal, Humanized
  • Humans
  • Interleukin Inhibitors*
  • Interleukin-17
  • Psoriasis* / drug therapy

Substances

  • Interleukin Inhibitors
  • Interleukin-17
  • Antibodies, Monoclonal, Humanized